Long-term Efficacy of Canakinumab in the Treatment of Schnitzler Syndrome
January 12, 2020
Citation: J Allergy Clin Immunol. 2020 Jan 12 [Epub ahead of print]

CAPSULE SUMMARY This 4-year long-term study confirms that canakinumab treatment effectively reduces the clinical signs and symptoms of Schnitzler syndrome, decreases inflammatory markers, and improves overall quality of life. However, canakinumab therapy requires close monitoring for infections.